Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2017-01-25 Report Publication Anno…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the company, Adocia, is organizing conference calls (in French and English) to provide an update on its programs following a previous announcement. The content focuses on scheduling these calls, clarifying the management's intent to discuss ongoing projects, and explicitly stating that no fundraising is planned. This structure—a brief announcement inviting stakeholders to a discussion about recent events or results—is characteristic of an Earnings Release (ER) or a general update announcement. Since it is explicitly setting up a conference call to discuss business updates and financial position (cash on hand), it functions as the precursor or summary to a more detailed earnings report, fitting the definition of an Earnings Release (ER) which provides key highlights and context for upcoming discussions. It is not a full transcript (CT), a full annual report (10-K), or a simple notice of a dividend (DIV). It is an announcement of a call to discuss results/updates.
2017-01-25 French
Communications during bidding periods / Other releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces strategic business model transformation, clinical trial updates, and future financing considerations (potential capital increase). This format, focusing on key operational and strategic news rather than comprehensive financial statements (like 10-K or IR) or formal voting results, strongly suggests an Earnings Release (ER) or a general corporate announcement. Since it details operational progress and future plans following a period (implied by the date January 19, 2017, likely following year-end 2016 results), it functions as an initial announcement of performance and outlook. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a specific regulatory filing like DIRS or DIV. Given the context of a press release detailing business updates and financial position (€58 million cash), Earnings Release (ER) is the most appropriate classification, as it precedes any detailed Management Discussion & Analysis (MDA) or formal filing. FY 2016
2017-01-19 English
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a strategic shift in the company's business model, updates on clinical projects (BC Lispro, BioChaperone Combo), and future plans, including potential fundraising. This content structure—announcing key operational and financial highlights for immediate public dissemination—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release detailing financial/operational performance updates rather than a full, comprehensive report (like 10-K or IR), ER is the most appropriate classification. It is not a transcript (CT), a formal audit report (AR), or a proxy statement (PSI). Given the content focuses on results and strategy updates, ER is preferred over the general fallback RNS.
2017-01-19 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated January 6th, 2017, detailing the status of shares and cash held in a liquidity account as of December 30, 2016, referencing a previous half-year report date (June 30, 2016). It also includes boilerplate information about the company (Adocia) and contact details. This type of announcement, which reports on specific, often routine, financial/market activities (like liquidity management or insider transactions, although this is about a liquidity agreement), is not a full financial report (10-K, IR) or an earnings release (ER). Since it reports on specific transactions/holdings related to the company's stock/capital management, it most closely aligns with either Director's Dealing (DIRS) if it were executive trades, or Capital/Financing Update (CAP) if it were a broader financing event. However, given the context of a liquidity agreement and the reporting of share/cash balances, it is a specific regulatory disclosure related to market operations. Since it is not a standard major filing, and it reports on specific share movements/holdings related to market stability, it fits best under a general regulatory disclosure category. Given the options, and noting that it is a specific, short update on share/cash balances under a liquidity agreement, it is not a standard DIRS (Director's Dealing). It is a specific regulatory update. If it were a transaction in own shares (POS), it would be clearer. Given the nature of reporting specific share balances under an agreement, and lacking a better fit among the primary financial reports, it falls into the general regulatory announcement category, RNS, as a specific, non-standard disclosure. However, upon re-evaluation, the content is a report on the status of shares held under a liquidity agreement, which is a form of capital management disclosure. Since it is not a formal dividend (DIV) or share issue (SHA/POS), and it is a specific update, RNS is the safest fallback. If we strictly interpret the content as reporting on the company's own shares being managed (even via a third party under agreement), it touches upon POS, but POS is usually for buybacks/sales. RNS is the most appropriate catch-all for specific, non-standard regulatory updates like this one.
2017-01-06 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and reports on the semi-annual balance of a liquidity contract (contrat de liquidité) with Kepler Chevreux, detailing the number of shares and cash held as of December 30, 2016, compared to June 30, 2016. This type of announcement, which reports on specific financial arrangements or transactions (like share buybacks/liquidity management) via a press release, fits best under 'Transaction in Own Shares' (POS) or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing. Since it specifically details the status of a liquidity agreement, which often involves share transactions (buying/selling own shares to maintain liquidity), POS is the most specific fit. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the context of managing share availability via a third party, POS is appropriate.
2017-01-06 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces scientific/pipeline updates regarding new combination drug projects for Type 1 diabetes treatment, including expected timelines for clinical studies (Q4 2017). It provides key highlights, quotes from management and external experts, and background information on the technology and related drugs. This format strongly indicates an initial announcement of significant company news, rather than a comprehensive financial report (10-K, IR), a formal voting result (DVA), or a transcript (CT). It is a typical Earnings Release (ER) or a general corporate update. Given that it focuses on R&D pipeline progress and future clinical milestones rather than specific quarterly financial figures, it aligns best with the general nature of an Earnings Release (ER) which often includes operational highlights alongside financial summaries, or potentially a Regulatory Filing (RNS) if it were purely regulatory. However, press releases announcing pipeline progress and future study initiation are most commonly categorized as Earnings Releases (ER) when they are the primary communication vehicle for operational updates, or sometimes Investor Presentations (IP) if it were a slide deck. Since this is a text-based announcement of operational progress and future plans, ER is the most fitting category among the provided options for a major corporate update that isn't a full financial report or a specific regulatory filing notice. Q4 2017
2017-01-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.